218 related articles for article (PubMed ID: 7295080)
1. Plasma middle molecules in asymptomatic and "sick" uremic patients.
Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
[TBL] [Abstract][Full Text] [Related]
2. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of uremic middle molecules in regular hemodialysis patients.
Asaba H; Alvestrand A; Fürst P; Bergström J
Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
[TBL] [Abstract][Full Text] [Related]
4. The effect of hemodialysis on endogenous middle molecules in uremic patients.
Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
[TBL] [Abstract][Full Text] [Related]
5. Middle molecule accumulation in uremia: an "extra uremic factor".
Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
[TBL] [Abstract][Full Text] [Related]
6. Accumulation and excretion of middle molecules.
Asaba H
Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
[TBL] [Abstract][Full Text] [Related]
7. Uremic middle molecules exist and are biologically active.
Bergström J; Fürst P; Zimmerman L
Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
[No Abstract] [Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Characterization of middle molecule compounds.
Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
[TBL] [Abstract][Full Text] [Related]
10. Uremic middle molecules: separation and quantitation.
Chapman GV; Farrell PC
Artif Organs; 1981; 4 Suppl():160-5. PubMed ID: 7295084
[TBL] [Abstract][Full Text] [Related]
11. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
Lustenberger N; Schindhelm K; Nordmeyer C; Schurek HJ; Stolte H
Artif Organs; 1981; 4 Suppl():110-4. PubMed ID: 7295076
[TBL] [Abstract][Full Text] [Related]
12. Determination of endogenous middle molecules in normal and uremic body fluids.
Fürst P; Zimmerman L; Bergström J
Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
[TBL] [Abstract][Full Text] [Related]
13. Chemical analytic approaches to the definition of uremic toxins.
Furst P; Bergstrom J; Gordon A; Zimmermann L
Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
[TBL] [Abstract][Full Text] [Related]
14. Transport of uremic toxins through conventional hemodialysis membranes.
Jörstad S; Smeby LC; Wideröe TE; Berg KJ
Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxic properties of plasma samples from uremic patients.
Delaporte C; Gros F; Jonsson C; Bergström J
Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
Jörstad S; Smeby LC; Wideröe TE
Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxic properties of plasma fractions from uremic patients.
Delaporte C; Gros F; Jonsson C; Bergström J
Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
[TBL] [Abstract][Full Text] [Related]
18. Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.
Tsao YT; Hsu YJ; Chu NF; Lai CH; Chiu JS; Lin SH
J Nephrol; 2008; 21(5):744-52. PubMed ID: 18949730
[TBL] [Abstract][Full Text] [Related]
19. Middle molecules in uremic serum, urine and dialysis fluid.
Migone L; Dall'taglio P; Buzio C
Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
[TBL] [Abstract][Full Text] [Related]
20. Middle molecular weight substances and uremic polyneuropathy.
Dukanović L; Petrović J; Potić J
Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
